MicroRNAs (miRNAs) are small regulatory molecules post-transcriptionally suppressing
mRNA activity. Many miRNAs in various organisms have been cloned but many unknown …

The purpose of this document is to update the “2014 AHA/ACC/HRS Guideline for the
Management of Patients With Atrial Fibrillation” S1. 3-1 (2014 AF Guideline) in areas for …

The current manuscript is the second update of the original Practical Guide, published in
2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of …

Background The risk of stroke is heterogeneous across different groups of patients with atrial
fibrillation (AF), being dependent on the presence of various stroke risk factors. We provide …

Background: Patients with end-stage kidney disease (ESKD) on dialysis were excluded from
clinical trials of direct oral anticoagulants for atrial fibrillation (AF). Recent data have raised …

Background Catheter ablation of atrial fibrillation is typically performed with uninterrupted
anticoagulation with warfarin or interrupted non–vitamin K antagonist oral anticoagulant …

Atrial fibrillation is found in a third of all ischaemic strokes, even more after post-stroke atrial
fibrillation monitoring. Data from stroke registries show that both unknown and untreated or …

Concepts and our approaches to stroke prevention in atrial fibrillation (AF) have changed
markedly over the last decade. There has been an evolution over the approach to stroke and …

Objective To investigate the associations between direct oral anticoagulants (DOACs) and
risks of bleeding, ischaemic stroke, venous thromboembolism, and all cause mortality …

Objective To examine clinical effectiveness and safety of apixaban 2.5 mg, dabigatran 110
mg, and rivaroxaban 15 mg compared with warfarin among patients with atrial fibrillation …